The fact that ChloraSolv, with very good efficacy, now can be used on venous leg ulcers and diabetic foot ulcers is very positive, not only for the patients and relatives but also for healthcare and society as this patient group is connected with large healthcare costs.

We are pleased to receive a positive confirmation from Lloyd’s register that ChloraSolv satisfies all required technological requirements.

RLS now has a detailed plan with activities for bringing ChloraSolv to the European markets in a structured manner.